Web23 hours ago · KEYNOTE-859 is a randomized, double-blind Phase 3 trial (ClinicalTrials.gov, NCT03675737) evaluating KEYTRUDA in combination with chemotherapy compared to placebo in combination with chemotherapy for the first-line treatment of patients with HER2-negative locally advanced unresectable or metastatic … WebMay 13, 2024 · A cancer-specific antibody binds to an antigen on the cell surface, gets internalized, and releases its potent payload to take effect. 41 Apart from the selective delivery of ADC, the mAb induces apoptosis by inhibiting signal transduction 42 or by the bystander killing effect, in which free payload in the cytosol permeates the plasma …
Enfortumab Vedotin Approved for Recurrent Bladder Cancer
WebApr 14, 2024 · Abstract. Despite provocative preclinical results, dose-limiting toxicities have precluded rational combinations of cytotoxic chemotherapies that increase DNA damage with DNA damage response (DDR) inhibitors. We hypothesized that tumor-targeted delivery of cytotoxic chemotherapy might enable tolerable and active combinations with DDR … WebJan 28, 2024 · Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing … thin bedspread
ADCs – From Lab to Clinical Development
WebAug 10, 2024 · This ADC can be used to treat advanced hormone receptor-positive, HER2-negative breast cancer, in people who have already received hormone therapy and at … WebNov 3, 2024 · Results from the phase 3 ASCENT trial showed that the ADC sacituzumab govitecan-hziy (Trodelvy) improved PFS versus standard-of-care single-agent chemotherapy, at 5.6 months versus 1.7 months ... WebNov 12, 2024 · Patients with pretreated, metastatic, triple-negative BC (TNBC) have a poor prognosis, and cytotoxic chemotherapy remains the mainstay for the systemic treatment … thin bedside table